Stay updated on Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page history now shows a new revision labeled v3.4.2, and the notices about government funding and the older v3.4.1 revision were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide maintenance notice about government funding status and a new site version (v3.4.1) were added, replacing the previous v3.4.0. No study-specific content or data appear to be altered.SummaryDifference0.3%

- Check28 days agoChange DetectedUI updates include showing the glossary and color-coded change highlights (green for additions, red for deletions) along with a new Revision: v3.4.0. The label 'No FEAR Act Data' has been updated (capitalization) and the previous v3.3.4 revision text was removed.SummaryDifference0.4%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision: v3.3.3 has been added to the page footer, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page history shows a new Revision: v3.3.2 replacing v3.3.1. No substantive changes to the study record or visible content are shown.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.